Table 3. Association of gene mutations with overall response to azacitidine.
| Univariate analysis | ||
|---|---|---|
| Mutated genes | OR (CI 95%) | P-value* |
| DNA methylation factors | ||
| TET2 | 1.07 (0.39–2.90) | 0.898 |
| DNMT3A | 1.78 (0.58–5.47) | 0.316 |
| IDH1 | 2.91 (0.25–33.41) | 0.391 |
| IDH2 | 3.03 (0.52–15.57) | 0.216 |
| Histone modulators | ||
| ASXL1 | 0.48 (0.12–1.96) | 0.307 |
| EZH2 | 0.24 (0.05–1.16) | 0.075 |
| Splicing factors | ||
| SF3B1 | 0.15 (0.02–1.27) | 0.081 |
| ZRSR2 | 0.43 (0.08–2.29) | 0.326 |
| U2AF1 | 2.33 (0.60–8.97) | 0.219 |
| Transcription factors | ||
| TP53 | 0.72 (0.24–2.16) | 0.552 |
| RUNX1 | 0.45 (0.13–1.54) | 0.201 |
| ETV6 | 0.33 (0.04–3.10) | 0.332 |
| Signaling factors | ||
| JAK2 | 3.03 (0.52–17.57) | 0.216 |
| CBL | 2.20 (0.35–13.94) | 0.401 |
| RAS family | ||
| KRAS | 0.33 (0.04–3.10) | 0.332 |
| NRAS | 0.21 (0.02–1.84) | 0.159 |
| Gene interactions | ||
| TET2mut + ASXL1wt | 0.98 (0.33–2.87) | 0.963 |
| TET2mut +ASXL1mut | 1.42 (0.19–10.63) | 0.730 |
| TET2wt +ASXL1mut | 0.21 (0.02–1.84) | 0.159 |
| DNMT3Amut + ASXL1wt | 1.5 (0.47–4.75) | 0.490 |
| DNMT3Amut + ASXL1mut | 2.33 | 1.000 |
| DNMT3Awt + ASXL1mut | 0.31 (0.06–1.56) | 0.156 |
| At least 1 mutation in DNA methylation genes | 3.53 (1.10–12.38) | 0.048** |
| N° of mutations in DNA methylation genes | 2.37 (1.10–5.36) | 0.038** |
| Multivariate analysis | ||
|---|---|---|
| Significant variables | OR (CI 95%) | P-value* |
| N° of cycles of azacitidine | 1.19 (1.10-1.35) | 0.006 |
| At least 1 mutation in DNA methylation genes | 4.76 (1.31-17.27) | 0.017 |
| N° total of gene mutations | 0.56 (0.33-0.94) | 0.028 |
Abbreviations: CI: confidence interval; OR: odds ratio; mut: mutated; wt: wild-type.
*P-value logistic regression results.
** Association with complete response.